The SIGMACEPTOR™-N Program
Combating neurological conditions: Alzheimer’s Disease, epilepsy, depression and
stroke

Anavex’s preclinical data has verified the anti-amnesic and neuroprotective action of sigma-1 receptor ligands in various in vitro systems and validated animal models. In our SIGMACEPTOR™-N program, Anavex is taking advantage of these properties to develop new drug candidates for Alzheimer’s Disease, epilepsy, depression and stroke. We have a strong portfolio of compounds targeting several Central Nervous System diseases.

Leading marketed therapies in Alzheimer’s Disease work partially through a sigma-1 receptor mechanism.